<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thalidomide is increasingly being used for the treatment of a variety of dermatologic conditions </plain></SENT>
<SENT sid="1" pm="."><plain>Some of the risks associated with thalidomide use, however, are still being uncovered </plain></SENT>
<SENT sid="2" pm="."><plain>Increased incidence of <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> following thalidomide use has recently been reported in the treatment of diseases with disease-related thrombotic risks, such as <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome </plain></SENT>
<SENT sid="3" pm="."><plain>We report a case of <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> resulting from thalidomide use in a patient with <z:e sem="disease" ids="C0030804" disease_type="Disease or Syndrome" abbrv="">cicatricial pemphigoid</z:e>, illustrating the potential concern for increased <z:mp ids='MP_0005048'>thrombosis</z:mp> following thalidomide use in the dermatology setting </plain></SENT>
</text></document>